secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvex, Inc. (MOVE)
CIK:        0001734750
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001213900-22-072330
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Movano Health reports Q3 net loss of $8.6M; progress on FDA submission and beta programs
--------------------------------------------------------------------------------

- Net loss of $8.6M ($0.26 diluted EPS) vs $5.2M ($0.16) in Q3 2021; no revenue.
- Cash and short-term investments $16.8M at Sept 30, down from $33.6M at Dec 31, 2021.
- Raised $1.9M via ATM facility in Q3; 33.5M shares outstanding.
- Plans to file for FDA clearance for heart rate and SpO2 in early 2023 after pivotal hypoxia study.
- Beta programs underway with Novant Health, Stanford, and two other partners; product launch expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1734750/000121390022072330/0001213900-22-072330-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1734750/000121390022072330/ea168495-8k_movanoinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-072330

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer